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4his review contains the conclusions from the published
bstracts with or without additions.
ORTALITY AND MORBIDITY
TTRIBUTABLE TO VALVULAR HEART DISEASE (VHD)
he annual National Hospital Discharge Survey showed
hat VHD is a significant cause of morbidity and mortality
n the U.S. Mortality and hospitalization for VHD have
ncreased since 1980, especially in women and the elderly
1). The causes of these trends and the implications for
linical and public health practice deserve further study.
EWER ISSUES IN VALVE DISEASE
mmunochemistry studies were performed to study cellular
echanisms (2). These show that VHD in humans involves
n endochondral bone process that is expressed as cartilage
n the mitral valve (MV) and bone in the atrial valve (AV).
his process may be regulated by the Lrp5 (low-density
ipoprotein receptor pathway; a chondrocytic differentiation
athway), which may contribute to the pathophysiology of
alve degeneration.
ORTIC STENOSIS (AS)
. The Euro Heart Survey (3) showed that: 1) women with
severe AS present at an older age and with more severe
symptoms, whereas men have more frequent comorbid-
ity and coronary disease; 2) the severity of AS did not
differ according to gender when considering indexed
valve area; 3) gender had no impact on the decision to
operate, even when adjusting for differences in patient
characteristics; and 4) one-year survival tended to be
higher in women.
. The hypothesis that aortic valve replacement (AVR)
prevents arteriovenous malformation bleeding in AS
patients was not supported in this study (4).
. In patients with severe AS, comorbidities, particularly
renal dysfunction, significantly impacted long-term out-
come (5). Early diagnosis and treatment of comorbidi-
ties may help to improve the prognosis in this patient
population.
. The combination of high levels of high sensitivity
C-reactive protein indicating systemic inflammation
plus low fetuin-A serum levels indicating systemic
calcification inhibitor deficiency were associated with
pronounced aortic valve calcification (6).
From the Griffith Center, Division of Cardiovascular Medicine, Department of
edicine, LAC  USC Medical Center, Keck School of Medicine at University of
outhern California, Los Angeles, California.. In the Multi-Ethnic Study of Atherosclerosis (MESA)
cohort, metabolic syndrome (MetS) and diabetes were
associated with an increased risk of aortic valve calcifi-
cation (AVC) and AVC prevalence was increased with
increasing number of MetS components (7). These
findings suggest that MetS is a risk factor for AVC and
raises the possibility that interventions targeting MetS
might decrease AVC progression.
ELECTED CLINICAL ISSUES IN VALVE DISEASE
. In this community study of patients with bicuspid aortic
valve and no or minimal hemodynamic abnormality,
long-term mortality is low but the incidence of cardio-
vascular events and AVR is high and is predicted by
baseline valve degeneration point score (8).
. The largest echocardiographic study to date in pa-
tients with systemic lupus erythematosus indicated
that antiphospholipid antibodies are associated with
mitral valve nodules and significant mitral regurgita-
tion (MR) but not with aortic valve abnormalities,
atherosclerosis, arterial stiffness, or left ventricular
structure or function (9).
ITRAL REGURGITATION
. In patients with ruptured chordae and partially flail MV,
most patients had a nonmyxomatous etiology that was
associated with older age, degenerative changes such as
mitral annular calcification and aortic sclerosis, and
short-term symptoms (10).
. In patients with ischemic mitral regurgitation (IMR),
survival after coronary artery bypass graft surgery was
influenced favorably by the presence of viable myocar-
dium (11). By contrast, adding MV repair to coronary
artery bypass graft did not affect survival except in
patients without viable myocardium, in whom it in-
creased early mortality.
. The Euro Heart Survey (12) showed that significant
differences exist between men and women with severe
MR: 1) women were referred at a more advanced
clinical state than men, although left ventricular func-
tion does not differ; 2) overall, the decision for surgery
did not differ according to gender; however, a decision
to operate was made less frequently in women with few
or no symptoms; 3) in women, MV repair is less
frequently performed and operative mortality tends to
be higher than in men.
. Angiotensin blockade by candesartan (n  44) or
ramipril (n  47) at maximum tolerated dose was
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regurgitant volume were determined. At one year, there
were no significant changes in regurgitant volume (13).
. Preoperative exercise duration was directly associated
with outcome after MV surgery among patients with
nonischemic MR; it predicted survival and symptom
persistence better than commonly documented clinical
variables (14). Thus, MV surgery is indicated not only in
patients reporting symptoms but in those with markedly
subnormal exercise duration even if symptoms are not
reported.
NFECTIVE ENDOCARDITIS (IE)
. Clinically unapparent acute brain infarction, including
large and multiple acute brain infarctions, seems to be
common in patients with left-sided IE. Routine brain
magnetic resonance imaging of all patients with left-
sided IE may be indicated (15).
. Echocardiography-guided risk stratification for sur-
gery was shown to be a cost-attractive treatment
strategy for IE; it improved outcome for an incre-
mental cost of $50,000/quality-adjusted life years
(16). The echocardiography-guided strategy remains
economically attractive across a broad range of as-
sumptions.
. Patients with type II diabetes mellitus had a significantly
higher prevalence of IE independent of chronic and
acute renal failure or valvular abnormalities (17). This
result is consistent with the increased vulnerability of
patients with diabetes mellitus to serious infections.
. Among individuals with IE, a history of stroke and
polymicrobial infection were significantly associated
with risk for embolism (18).
ERCUTANEOUS PROCEDURES
. The Percutaneous Septal Sinus Shortening (PS3 system)
was effective in the amelioration of functional MR in an
ovine model (19). The procedure uses standard catheter
Abbreviations and Acronyms
AS  aortic stenosis
AV  atrial valve
AVC  aortic valve calcification
AVR  aortic valve replacement
EVEREST  Endovascular Valve Edge-to-Edge Repair
Study
IE  infective endocarditis
IMR  ischemic mitral regurgitation
MESA  Multi-Ethnic Study of Atherosclerosis
MetS  metabolic syndrome
MR  mitral regurgitation
MV  mitral valve
PHV  prosthetic heart valve
VHD  valvular heart diseasetechniques and can be deployed largely under fluoro-scopic guidance. In addition, the bridge element allows
direct and precise septal-lateral mitral annular shorten-
ing to a diameter optimal for MR reduction.
. Percutaneous edge-to-edge mitral valve repair with the
Evalve MitraClip was accomplished successfully in pa-
tients with functional MR in the Endovascular Valve
Edge-to-Edge Repair Study (EVEREST 1) trial. In
this study, MR was reduced without major adverse
events (20).
. Pulmonary hypertension with an excessive transpulmo-
nary gradient is not uncommon in patients with mitral
stenosis; women seem to have a much greater risk of
developing this problem (21). Despite higher right-
sided pressures and worse symptoms, mitral valvulo-
plasty is equally successful and provided sustained ben-
efit in this population of patients.
. “Significant (3 or 4) aortic regurgitation is common
after Cribier-Edwards prosthetic heart valve (PHV)
implantation. It is noteworthy that aortic regurgitation
1 was seen with a larger diameter PHV. Appropri-
ate device sizing and advanced device designs may
reduce the incidence and degree of aortic regurgitation
after PHV implantation” (22).
URGERY
alvular Regurgitation
. Survival after annuloplasty for IMR was adversely af-
fected by global left ventricular dysfunction and postin-
farct remodeling (23). Mitral regurgitation returns in a
substantial proportion of patients, emphasizing the ven-
tricular rather than valvar nature of this disease.
. Surgical repair of IMR with the novel, asymmetric
Carpentier-McCarthy-Adams IMR ET Logix Annulo-
plastic Ring provides “excellent early results” with effec-
tive reduction of anteroposterior dimension, leaflet teth-
ering, and left ventricular volume (24). “This novel,
etiology-specific strategy may result in improved out-
comes in IMR patients, including lower incidence of
recurrent MR.”
. Mitral valve repair is associated with lower long-term
incidence of cardiovascular thromboemboli than me-
chanical PHV and with a smaller benefit compared with
bioprosthetic PHV (25). However, there is a high rate
of cardiovascular thromboemboli in all types of surger-
ies, including mitral valve repair, within the first post-
operative month, and this extends to the first six months
after surgery of MR and requires relatively prolonged
anticoagulation for cardiovascular thromboemboli pre-
vention in the first six postoperative months.
. Tricuspid valve annuloplasty with the Edward MC3
ring was effective in the treatment of functional tricus-
pid regurgitation (26). This new surgical treatment may
result in improved outcomes in patients with functional
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. In a large observational study of Medicare beneficiaries
that accounted for patient and hospital-level factors
with follow-up extending to 13 years, patients receiving
bioprosthetic valves had a modestly lower risk of death
and lower rates of subsequent stroke, embolism, and
hemorrhage, but a higher risk of repeat AVR. Given the
low rate of repeat AVR, these data support broader use
of bioprosthetic valves in older patients (27).
. Inadequate anticoagulation was the predominant cause
of prosthetic valve thrombosis. Successful thrombolysis
was achieved at low risk of complications with intrave-
nous thrombolytic therapy for both mitral and aortic
valve thrombosis and in all types of prosthesis (28).
Hence, we recommend thrombolytic therapy as a safe
and effective nonsurgical method of treatment for pros-
thetic valve thrombosis.
. In a randomized trial, rapid fibrinolytic therapy (large
initial dose of streptokinase of 1.5 million U followed if
required by 0.1 million U/h) was more efficacious in
achieving a complete clinical response (p  0.047) than
the standard protocol (0.25 million U given 30 min
followed by 0.1 million U/h) for treatment of a first
episode of PHV thrombosis (29).
. Severe valve prosthesis-patient mismatch, valve area
0.65 cm2/m2, was a strong predictor of the worst
long-term survival (47.4% at a mean follow-up of 6.7
years) among patients undergoing mechanical AVR
(30). Valve prosthesis-patient mismatch was most likely
to occur in small valve sizes and can be avoided at the
time of surgery.
ypertrophic Cardiomyopathy
. Intrinsic mitral valve pathology is commonly observed
in hypertrophic cardiomyopathy patients with symp-
tomatic obstruction undergoing myectomy. Echocardi-
ography can identify MV features predictive of MV
repair (31). The relative contribution of MV replace-
ment and comorbidities on outcome needs further
evaluation.
. “Isolated septal myectomy is an extremely safe operation
with little morbidity and no mortality and should be
considered the first choice in the treatment of symp-
tomatic patients with hypertropic obstructive cardiomy-
opathy” (32).
ther Surgery
. The Euro Heart Survey (33) showed: 1) surgery was
denied in as many as one-half of patients with severe,
symptomatic MR; 2) older age and comorbidity might
be valid ground for deciding against surgery in certain
cases; and 3) conversely, moderately decreased left
ventricular ejection fraction, congestive heart failure,
and moderate symptoms (New York Heart Association
1functional class II) should not lead to denial of surgery
according to current guidelines.
. Major patient risk factors for postoperative dialysis after
coronary artery bypass graft were identified and were
converted into a simple, accurate bedside risk tool that
may facilitate improved assessment regarding risks of
postoperative dialysis (34).
. Population-based observational study quantified the
long-term prognosis of patients with severe left ventric-
ular dysfunction (grade 4 left ventricle) out to 10 years
after surgical revascularization (35). Adjunctive thera-
pies to revascularization may be needed.
. The International Registry of Acute Aortic Dissection
risk model predicts in-hospital mortality using a math-
ematical model and may be useful for considering risks
and benefits of high-risk surgery (36).
. Observant Jehovah’s Witnesses who underwent cardiac
surgery without blood transfusion compared with non-
Jehovah’s Witness patients returned to the operating
room for bleeding more often but had a similar inci-
dence of in-hospital and long-term death (37).
ddress correspondence to: Dr. Shahbudin H. Rahimtoola,
niversity of Southern California, 2025 Zonal Avenue, Los
ngeles, California 90033.
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